These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38614823)

  • 1. Re: FGFR Inhibition Augments Anti-PD-1 Efficacy in Murine FGFR3-mutant Bladder Cancer by Abrogating Immunosuppression.
    St-Laurent MP; Black PC
    Eur Urol; 2024 Aug; 86(2):184-185. PubMed ID: 38614823
    [No Abstract]   [Full Text] [Related]  

  • 2. FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression.
    Okato A; Utsumi T; Ranieri M; Zheng X; Zhou M; Pereira LD; Chen T; Kita Y; Wu D; Hyun H; Lee H; Gdowski AS; Raupp JD; Clark-Garvey S; Manocha U; Chafitz A; Sherman F; Stephens J; Rose TL; Milowsky MI; Wobker SE; Serody JS; Damrauer JS; Wong KK; Kim WY
    J Clin Invest; 2024 Jan; 134(2):. PubMed ID: 38226620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.
    Wang L; Gong Y; Saci A; Szabo PM; Martini A; Necchi A; Siefker-Radtke A; Pal S; Plimack ER; Sfakianos JP; Bhardwaj N; Horowitz A; Farkas AM; Mulholland D; Fischer BS; Oh WK; Sharma P; Zhu J; Galsky MD
    Eur Urol; 2019 Nov; 76(5):599-603. PubMed ID: 31272788
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Kacew A; Sweis RF
    Front Immunol; 2020; 11():575258. PubMed ID: 33224141
    [No Abstract]   [Full Text] [Related]  

  • 5. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
    Song Y; Peng Y; Qin C; Wang Y; Yang W; Du Y; Xu T
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37777251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
    Rose TL; Weir WH; Mayhew GM; Shibata Y; Eulitt P; Uronis JM; Zhou M; Nielsen M; Smith AB; Woods M; Hayward MC; Salazar AH; Milowsky MI; Wobker SE; McGinty K; Millburn MV; Eisner JR; Kim WY
    Br J Cancer; 2021 Oct; 125(9):1251-1260. PubMed ID: 34294892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mathematical Modeling of Tumor Immune Interactions: The Role of Anti-FGFR and Anti-PD-1 in the Combination Therapy.
    Li C; Ren Z; Yang G; Lei J
    Bull Math Biol; 2024 Aug; 86(9):116. PubMed ID: 39107447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
    Komura K; Hirosuna K; Tokushige S; Tsujino T; Nishimura K; Ishida M; Hayashi T; Ura A; Ohno T; Yamazaki S; Nakamori K; Kinoshita S; Maenosono R; Ajiro M; Yoshikawa Y; Takai T; Tsutsumi T; Taniguchi K; Tanaka T; Takahara K; Konuma T; Inamoto T; Hirose Y; Ono F; Shiraishi Y; Yoshimi A; Azuma H
    Mol Cancer; 2023 Nov; 22(1):185. PubMed ID: 37980528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.
    Pouessel D; Neuzillet Y; Mertens LS; van der Heijden MS; de Jong J; Sanders J; Peters D; Leroy K; Manceau A; Maille P; Soyeux P; Moktefi A; Semprez F; Vordos D; de la Taille A; Hurst CD; Tomlinson DC; Harnden P; Bostrom PJ; Mirtti T; Horenblas S; Loriot Y; Houédé N; Chevreau C; Beuzeboc P; Shariat SF; Sagalowsky AI; Ashfaq R; Burger M; Jewett MA; Zlotta AR; Broeks A; Bapat B; Knowles MA; Lotan Y; van der Kwast TH; Culine S; Allory Y; van Rhijn BW
    Ann Oncol; 2016 Jul; 27(7):1311-6. PubMed ID: 27091807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
    Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
    Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel immune microenvironment signature predicting survival and therapeutic options for bladder cancer.
    Yan Y; Huang Z; Cai J; Tang P; Zhang F; Tan M; Shen B
    Aging (Albany NY); 2020 Dec; 13(2):2780-2802. PubMed ID: 33408272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants.
    Yang Y; Suhasini AN; Jiang Z; Liu N; Rosconi M; Zhang B; Li Y; Dudgeon D; Seong C; Kim S; Rafique A; Huang T; Bhosle S; Krueger P; Ullman E; Olson W; Lin JC; Shen Y; Daly C
    Cancer Res; 2024 Jul; 84(13):2169-2180. PubMed ID: 39082679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
    Balasooriya ER; Wu Q; Ellis H; Zhen Y; Norden BL; Corcoran RB; Mohan A; Martin E; Franovic A; Tyhonas J; Lardy M; Grandinetti KB; Pelham R; Soroceanu L; Silveira VS; Bardeesy N
    Clin Cancer Res; 2024 May; 30(10):2181-2192. PubMed ID: 38437671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
    Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
    Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor receptor (
    Al-Obaidy KI; Cheng L
    J Clin Pathol; 2021 Aug; 74(8):491-495. PubMed ID: 33731335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.
    Bergman DR; Wang Y; Trujillo E; Fernald AA; Li L; Pearson AT; Sweis RF; Jackson TL
    Front Immunol; 2024; 15():1358019. PubMed ID: 38515743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
    Qin Q; Patel V; Galsky MD
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):503-512. PubMed ID: 32436413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer.
    Lin H; Fu L; Zhou X; Yu A; Chen Y; Liao W; Shu G; Zhang L; Tan L; Liang H; Wang Z; Deng Q; Wang J; Jin M; Chen Z; Wei J; Cao J; Chen W; Li X; Li P; Lu J; Luo J
    Cancer Lett; 2024 Jul; 593():216807. PubMed ID: 38462037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
    Bednova O; Leyton JV
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.